Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications

Executive Summary

Second quarter Otezla sales came in slightly lower than consensus, but Celgene believes changes in inventory levels will smooth out for the remainder of 2018. However, the company is reconsidering its pursuit of IBD indications for Otezla in deference to its potential blockbuster ozanimod.

You may also be interested in...



With Celgene Acquisition Closed, Bristol Faces Major Milestones

Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue. 

Pharma Q3 Results Preview: Biogen, Gilead, Celgene

Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon. 

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123492

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel